Second messenger systems in brains of patients with Parkinson's or Huntington's disease.
Alterations in protein kinase C (PKC) and myo-inositol 1,4,5-trisphosphate (IP3) receptors were studied in the autopsied human striata from 21 patients with Parkinson's disease (PD) (Yahr III, IV, and V), 8 patients with Huntington's disease (HD), and 23 age-matched and postmortem time-matched nonneurological controls. The concentrations of PKC and IP3 receptors were determined using [3H]4 beta-phorbol 12,13-dibutyrate (PDBu) and [3H]IP3 as respective ligands. Both the specific [3H]-PDBu and [3H]IP3 bindings were significantly reduced in the striata of Yahr V patients with dementia (PDD) and in that of HD patients, as compared to findings in the controls. These bindings were unchanged when all the PD patients without dementia, Yahr (III plus IV) patients, or Yahr V patients without dementia were compared with evidence from the controls. Immunoquantification of four PKC subspecies (alpha, beta I, beta II, and gamma) in the HD putamen revealed a selective reduction in the beta II-PKC immunoreactions. These results are supported by immunohistochemical findings in the rat brain that beta II-PKC is expressed in the striatal gabaergic efferent pathway, while the alpha-PKC is present in the nigrostriatal dopaminergic neurons. The neurochemical pathophysiology of PD differs between patients with and without dementia.
Tanaka
C
C
Department of Pharmacology, Kobe University School of Medicine, Japan.
Nishino
N
N
Hashimoto
T
T
Kitamura
N
N
Yoshihara
C
C
Saito
N
N
D000368:Aged; D000818:Animals; D001921:Brain / Q000473:pathology / Q000503:physiopathology*; D001931:Brain Mapping; D002118:Calcium / Q000502:physiology; D016923:Cell Death / Q000502:physiology; D003342:Corpus Striatum / Q000473:pathology / Q000503:physiopathology; D005260:Female; D006801:Humans; D006816:Huntington Disease / Q000473:pathology / Q000503:physiopathology*; D015544:Inositol 1,4,5-Trisphosphate / Q000493:pharmacokinetics; D008297:Male; D008875:Middle Aged; D009410:Nerve Degeneration / Q000502:physiology; D018377:Neurotransmitter Agents / Q000502:physiology; D010300:Parkinson Disease / Q000473:pathology / Q000503:physiopathology*; D015240:Phorbol 12,13-Dibutyrate / Q000493:pharmacokinetics; D011493:Protein Kinase C / Q000502:physiology; D051381:Rats; D015290:Second Messenger Systems / Q000502:physiology*; D013378:Substantia Nigra / Q000473:pathology / Q000503:physiopathology
D018377:Neurotransmitter Agents; D015240:Phorbol 12,13-Dibutyrate; D015544:Inositol 1,4,5-Trisphosphate; D011493:Protein Kinase C; D002118:Calcium